One step closer to an experimental infection system for Hepatitis B Virus? --- the identification of sodium taurocholate cotransporting peptide as a viral receptor

Chen, Pei‐Jer; Wu, T. C.

doi:10.1186/2045-3701-3-2

Cited by 6 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Schieck et al [ 11 ] demonstrated that HBV virus hepatotropism is mediated through specific binding of the myristoylated N -terminal preS1-domain of the HBV L-protein to a hepatocyte specific, but at that time unknown, receptor. In 2013, Chen et al [ 13 ] proclaimed a sodium taurocholate cotransporting peptide (NTCP) as a potential viral receptor by identifying a stretch of 10 amino acids in the NTCP transmembrane domain as the motive directly interacting with the preS1 peptide. In the future, there is the necessity to understand the interaction of NTCP with HBV envelope proteins and other cellular proteins.…”

Section: Hepatitismentioning

confidence: 99%

Current Status in the Therapy of Liver Diseases

Uhl

Fricker

Haberkorn

et al. 2014

IJMS

View full text Add to dashboard Cite

Hepatic diseases, like viral hepatitis, autoimmune hepatitis, hereditary hemochromatosis, non-alcoholic fatty liver disease (NAFLD) and Wilson’s disease, play an important role in the development of liver cirrhosis and, hence, hepatocellular carcinoma. In this review, the current treatment options and the molecular mechanisms of action of the drugs are summarized. Unfortunately, the treatment options for most of these hepatic diseases are limited. Since hepatitis B (HBV) and C (HCV) infections are the most common causes of liver cirrhosis and hepatocellular carcinoma, they are the focus of the development of new drugs. The current treatment of choice for HBV/HCV infection is an interferon-based combination therapy with oral antiviral drugs, like nucleos(t)ide analogues, which is associated with improving the therapeutic success and also preventing the development of resistances. Currently, two new protease inhibitors for HCV treatment are expected (deleobuvir, faldaprevir) and together with the promising drug, daclatasvir (NS5A-inhibitor, currently in clinical trials), adequate therapy is to be expected in due course (circumventing the requirement of interferon with its side-effects), while in contrast, efficient HBV therapeutics are still lacking. In this respect, entry inhibitors, like Myrcludex B, the lead substance of the first entry inhibitor for HBV/HDV (hepatitis D) infection, provide immense potential. The pharmacokinetics and the mechanism of action of Myrcludex B are described in detail.

show abstract

Section: Hepatitismentioning

confidence: 99%

Current Status in the Therapy of Liver Diseases

Uhl

Fricker

Haberkorn

et al. 2014

IJMS

View full text Add to dashboard Cite

show abstract

“…Several commentaries by others on the NTCP findings have since been published [13][14][15][16] . And, several labs, in as yet unpublished studies, have confirmed the ability of recombinant NTCP to facilitate entry of HBV and HDV into otherwise non-susceptible cell lines.…”

Section: What the Hosts Providementioning

confidence: 99%

Virus entry mediated by hepatitis B virus envelope proteins

Taylor¹

2013

WJG

View full text Add to dashboard Cite

Hepatitis B virus (HBV), a major cause of human liver disease worldwide, encodes three envelope proteins needed for the attachment and entry of the virus into susceptible host cells. A second virus, hepatitis delta virus, which is known to enhance liver disease in HBV infected patients, diverts the same HBV envelope proteins to achieve its own assembly and infection. In the lab, lentiviral vectors based on human immunodeficiency virus type 1 can be assembled using the HBV envelope proteins, and will similarly infect susceptible cells. This article provides a partial review and some personal reflections of how these three viruses infect and of how recipient cells become susceptible, along with some consideration of questions that remain to be answered.

show abstract

“…Yin et al identified HBV with a C2964A mutation in the preS1 region as a novel factor associated with HCC [56]; this mutation has also been reported in the present study. The preS1 region (residues 1-47) is necessary for binding with the NTCP receptor for successful infection [57,58]. Thus, a preS1 peptide-based vaccine could be an alternative strategy to prevent HBV infection [22,59].…”

Section: Discussionmentioning

confidence: 99%

PreS1 Mutations Alter the Large HBsAg Antigenicity of a Hepatitis B Virus Strain Isolated in Bangladesh

Hossain

Mahmud

Nazir

et al. 2020

IJMS

View full text Add to dashboard Cite

Mutations in the hepatitis B virus (HBV) genome can potentially lead to vaccination failure, diagnostic escape, and disease progression. However, there are no reports on viral gene expression and large hepatitis B surface antigen (HBsAg) antigenicity alterations due to mutations in HBV isolated from a Bangladeshi population. Here, we sequenced the full genome of the HBV isolated from a clinically infected patient in Bangladesh. The open reading frames (ORFs) (P, S, C, and X) of the isolated HBV strain were successfully amplified and cloned into a mammalian expression vector. The HBV isolate was identified as genotype C (sub-genotype C2), serotype adr, and evolutionarily related to strains isolated in Indonesia, Malaysia, and China. Clinically significant mutations, such as preS1 C2964A, reverse transcriptase domain I91L, and small HBsAg N3S, were identified. The viral P, S, C, and X genes were expressed in HEK-293T and HepG2 cells by transient transfection with a native subcellular distribution pattern analyzed by immunofluorescence assay. Western blotting of large HBsAg using preS1 antibody showed no staining, and preS1 ELISA showed a significant reduction in reactivity due to amino acid mutations. This mutated preS1 sequence has been identified in several Asian countries. To our knowledge, this is the first report investigating changes in large HBsAg antigenicity due to preS1 mutations.

show abstract

One step closer to an experimental infection system for Hepatitis B Virus? --- the identification of sodium taurocholate cotransporting peptide as a viral receptor

Cited by 6 publications

References 7 publications

Current Status in the Therapy of Liver Diseases

Current Status in the Therapy of Liver Diseases

Virus entry mediated by hepatitis B virus envelope proteins

PreS1 Mutations Alter the Large HBsAg Antigenicity of a Hepatitis B Virus Strain Isolated in Bangladesh

Contact Info

Product

Resources

About